DISCONTINUED: Stages of Development for LU AA24493

The drug development process can be thought of as a series of stages, and drugs must successfully pass through each stage to become available to patients. This treatment has been evaluated, and the program has been discontinued. Thus, it is not in the pipeline.

Link to previous study

2009: A multicenter, double-blind, placebo-controlled, phase II study of Lu AA24493 was conducted in Germany, Austria, and Italy. The primary objective of the study is to evaluate the safety and tolerability of Lu AA2493 in patients with FA.

2011: The study concluded, and the company announced in a press release that based on the trial results that they were discontinuing the program in FA.

Biomarkers, such as frataxin, or measures for oxidative stress and ataxia ratings did not differ between cEPO and placebo groups.